Actinium Pharmaceuticals Inc (ATNM) was Initiated by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $5. ROTH Capital advised their investors in a research report released on Aug 25, 2016.
Actinium Pharmaceuticals Inc closed down -0.0399 points or -2.38% at $1.6401 with 2,98,901 shares getting traded on Tuesday. Post opening the session at $1.7, the shares hit an intraday low of $1.64 and an intraday high of $1.7 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Apr 18, 2016, C. David Nicholson, (director) purchased 5,000 shares at $2.00 per share price. According to the SEC, on Apr 18, 2016, Sergio Traversa (director) purchased 3,000 shares at $2.02 per share price. On Apr 18, 2016, Kaushik J Dave (CEO) purchased 10,000 shares at $2.02 per share price, according to the Form-4 filing with the securities and exchange commission.
Actinium Pharmaceuticals Inc. (Actinium) is a biopharmaceutical company engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Company’s products include Actimab-A an antibody-drug construct containing actinium 225 (Ac-225) and Iomab-B an antibody-drug construct containing iodine 131 (I-131). As of December 31 2014 Actinium’s Actimab-A was in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. As of December 31 2014 the Company had four product candidates in clinical trials: Actimab-A (HuM195-Ac-225) Iomab-B (BC8-I-131) BC8-Y-90 and BC8-SA. As of December 31 2014 BC8-Y-90 and BC8-SA were in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).